Stocks Gapping Up 2017-09-26
ACTA Actua Corporation (ACTA) announced that it has entered into separate agreements to sell its three majority-owned businesses for an aggregate of $549 million in cash. Today’s announcement is the result of the Board’s comprehensive review of a range of strategic options to maximize stockholder value, which was undertaken with the support of independent financial and legal advisors.
BABA Alibaba (BABA) said late Monday that it agreed to increase its stake in its logistics affiliate Cainiao Smart Logistics Network to 51% from 47% by investing RMB5.3 billion ($807 million).
ASNA Ascena Retail Group (ASNA) reported Q4 EPS of $0.05, $0.08 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.66 billion versus the consensus estimate of $1.57 billion.
BTX BioTime (BTX) reported Tuesday that treated patients from the Renevia pivotal trial in Europe retained an average of 70% of the transplanted volume at 12 months.
CAPR Capricor Therapeutics, Inc. (CAPR) which is developing biological therapies for Duchenne muscular dystrophy (DMD) and other rare diseases, today announced that the national principal investigator for its HOPE-2 Trial will be Craig M. McDonald, M.D., a distinguished thought leader in the clinical management of neuromuscular diseases, including muscular dystrophies, and the development of novel outcome measures for DMD clinical trials.
CDXC ChromaDex Corp. (CDXC) announced today that the initial results of its second human clinical study of NIAGEN® nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.
NDRO Enduro Royalty Trust (NDRO) today announced a special cash distribution to the holders of its units of beneficial interest of $1.150005 per unit, payable on October 20, 2017 to unitholders of record on October 5, 2017. The special distribution represents net proceeds allocable to Trust unitholders from the divestiture of certain oil and natural gas properties in the Permian Basin (the “Divestiture Properties”) that constituted part of the properties burdened by the Trust’s 80% net profits interest. At a special meeting of the Trust unitholders on August 30, 2017, the Trust unitholders approved (i) eight transactions pursuant to which Enduro Resource Partners LLC (“Enduro”), the sponsor of the Trust, would sell the Divestiture Properties, (ii) the release of the Trust’s 80% net profits interest in the Divestiture Properties, and (iii) related proposals to effect the sale transactions in exchange for the Trust receiving 80% of the net proceeds of the sale of the Divestiture Properties.
FCSC Fibrocell Science, Inc. (FCSC) a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported interim results in its Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Three adult non-collagenous (NC)1+ patients have been dosed with a single intradermal injection session of FCX-007 in the margins of and across targeted wounds, as well as in separate intact skin sites. Five wounds were treated on the three subjects, ranging in size from 4.4cm2 to 13.1cm2.
GHL Greenhill & Co. (GHL) will be to borrow $300M under a Term Loan B structure, with funds (along with $10M in share purchases by both the chairman and CEO) to be used to repay all existing bank debt and buy back up to $235M of common stock.
HIMX Himax Technologies (HIMX) said it has reached an agreement to sell its stake in a China-based operation for $32 million. Himax anticipates a pre-tax gain of approximately $23 million. Gain after tax is estimated to be $20.7 million, representing a contribution of $0.12 GAAP net income per diluted ADS.
ICPT Intercept Pharmaceuticals (ICPT) received a price-target from RBC Capital Markets after the biopharmaceutical company on Monday emphasized the recommended dosing for its Ocaliva treatment for a rare liver disease called primary biliary cholangitis, warning of the risk of dose-related liver adverse reactions in late-stage patients with moderate or severe hepatic impairment.
IZEA IZEA, Inc (IZEA) operator of IZEAx®, the premier online marketplace connecting brands and publishers with influential content creators, is reporting several high-profile contract wins. During the third quarter, IZEA has received a seven-figure contract renewal with a Fortune 500 financial services company for custom content and influencer marketing services. The company has also signed contracts in excess of a quarter million dollars with a Fortune 500 media company, a multi-national food conglomerate and a consumer products manufacturer. In addition, IZEA has established a new master services agreement with a top 10 global retailer and the related contract for a six-figure influencer marketing campaign.
KTOS Kratos Defense & Security Solutions (KTOS) said that its unmanned systems division has recently received $9.7 million in contract awards from National Security related customers for multiple high performance unmanned aerial drone system aircraft. Work under the contract awards will be performed at secure manufacturing facilities, customer sites, and other locations. No additional information will be provided related these contract awards.
MBRX Moleculin Biotech (MBRX) said the U.S. Food and Drug Administration (FDA) approved its application to begin clinical trials of Annamycin in the treatment of relapsed or refractory Acute Myeloid Leukemia (AML).
TEUM Pareteum Corporation (TEUM) today announced that it has signed a 5-year agreement with a leading Eastern European telecommunications company with broad holdings in the telecommunications, broadcasting, real estate and industrial markets, to provide the Pareteum Managed Services Platform. Pareteum's Managed Services Platform will enable this Eastern European telco to provide wireless services to existing and new Mobile Virtual Network Operators (MVNOs) in its geographic market, serving the needs of consumer mobile, enterprises and Internet of Things (IoT) devices to enable the move to a wirelessly connected smart city in the region. The initial on-boarding of subscribers is expected to commence at the beginning of second quarter 2018.
PSTI Pluristem Therapeutics (PSTI) said Tuesday it plans to submit an Investigational New Drug and Clinical Trial Application for its phase III trial in PLX-PAD cells as a treatment for muscle recovery following arthroplasty for hip fracture in the coming months.
PSDV pSivida (PSDV) signed an agreement with an unnamed major global pharmaceutical company to develop two glaucoma drugs with pSivida's proprietary sustained release technology. The terms of the partnership include upfront payments to pSivida of $750,000 for initial development and potential additional payments totaling $200,000 if all subsequent development activities are conducted.
RHT Red Hat (RHT) posted fiscal second-quarter revenue and adjusted earnings that topped the expectations of Wall Street analysts on higher demand for cloud computing and other emerging technologies. Non-GAAP net income, which excludes some exceptional items, for the quarter ended August 31 was $138 million, or $0.77 per diluted share, compared with $101 million, or $0.55 per diluted share, in the same quarter a year earlier, the company said on Monday after the market closed. Analysts in a Capital IQ poll had predicted adjusted earnings per share of $0.67.
SWM Schweitzer-Mauduit (SWM) DA Davidson initiated Schweitzer-Mauduit (SWM) coverage with Buy and target $47
SNX Synnex Corp (SNX) earnings and outlook topped Wall Street estimates. The company reported fiscal third-quarter net income of $75.2 million , or $1.87 a share, compared to $58.7 million , or $1.47 a share, in the year-ago period. Adjusted earnings were $2.16 a share. Revenue rose to $4.28 billion from $3.67 billion in the year-ago period. Analysts surveyed by FactSet had estimated $1.97 a share on revenue of $4 billion . For the fiscal fourth quarter, Synnex estimates adjusted earnings of $2.63 to $2.73 a share on revenue of $4.75 billion to $4.95 billion .
TSEM Tower Semiconductor (TSEM) Credit Suisse initiated Tower Semiconductor (TSEM) coverage with Outperform and target $36
Copyright dailystockplays.com All Rights Reserved